



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/541,657

03/03/2006

Robert M. Jones

34.US5.PCT

4098

26204 7590 01/19/2011
FISH & RICHARDSON P.C.
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER

JARRELL, NOBLE E

ART UNIT

PAPER NUMBER

1624

NOTIFICATION DATE

DELIVERY MODE

01/19/2011

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PATDOCTC@fr.com

Office Action Summary	Application No.	Applicant(s)	
	10/541,657	JONES ET AL.	
	Examiner	Art Unit	
	NOBLE JARRELL	1624	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 05 January 2011.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-5, 12-14, 16-66, 73, 74, 78-85, 87-92 and 100-109 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-5, 12-14, 16-66, 73, 74, 78-85, 87-92 and 100-109 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>5 January 2011</u> | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1624

DETAILED ACTION

Response to Amendment

1. The current action is written in response to amendment filed 5 January 2011.

Priority

2. The priority date of the instant application is 14 January 2003.

Claim Objections

3. Claims 1-5, 12-14, 16-66, 73, 74, 78-85, 87-92, and 100-109 are objected to because of the following informalities: In claim 1, the phrase "Formula (Ia) and pharmaceutically acceptable salts, hydrate, and solvates thereof" should be --Formula (Ia) or a pharmaceutically acceptable salt, hydrate, or solvate thereof--. In claims 73 and 74, the language "following compounds and pharmaceutically acceptable salts, hydrates, and solvates thereof" should be replaced with --following compounds, a pharmaceutically acceptable salt, hydrate, or solvate thereof--. In addition, the word "and" after the penultimate compound of claims 73 and 74 should be replaced with the word --or-- because claims 73 and 74 use the language "selected from", not the phrase "selected from the groups consisting of".

Appropriate correction is required.

Claim Rejections - 35 USC § 112

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 1-5, 12-14, 16-66, 73, 74, 78-85, 87-92, and 100-109 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the preparation of a pharmaceutically acceptable salt, does not reasonably provide enablement for preparation of a solvate or hydrate of a compound embraced by formula (Ia). The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

Art Unit: 1624

The factors to be considered in determining whether a disclosure meets the enablement requirements of 35 U.S.C. 112, first paragraph, have been described in *In re Wands*, 858 F.2d 731, 8 USPQ2d 1400 (Fed. Cir., 1988). The court in *Wands* states, "Enablement is not precluded by the necessity for some experimentation, such as routine screening. However, experimentation needed to practice the invention must not be undue experimentation. The key word is 'undue', not 'experimentation'" (*Wands*, 8 USPQ2d 1404). Clearly, enablement of a claimed invention cannot be predicated on the basis of quantity of experimentation required to make or use the invention. "Whether undue experimentation is needed is not a single, simple factual determination, but rather is a conclusion reached by weighing many factual considerations" (*Wands*, 8 USPQ2d 1404). Among these factors are: (1) the nature of the invention; (2) the breadth of the claims; (3) the state of the prior art; (4) the predictability or unpredictability of the art; (5) the relative skill of those in the art; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary.

Consideration of the relevant factors sufficient to establish a *prima facie* case for lack of enablement is set forth herein below:

(1) *The nature of the invention and (2) the breadth of the claims:*

The claims are drawn to a compound in which a pyrimidine ring is modified with a NH-C(=NR⁸)NHR⁷ at its 5-position and nitrogen-containing heterocyclic ring at its 4-position.

Thus, the claims taken together with the specification imply that a pharmaceutically acceptable salt, hydrate, or a solvate of these compounds can be prepared.

(3) *The state of the prior art and (4) the predictability or unpredictability of the art:*

Hildesheim et al. (US 7056942, issued 6 June 2006) describe that solvate or hydrate formation/existence is unpredictable (column 2, line 60 to column 3, line 14).

(5) *The relative skill of those in the art:*

Those of relative skill in the art are those with level of skill of the authors of the references cited to support the examiner's position (MD's, PhD's, or those with advanced degrees and the requisite experience in solvate or hydrate formation).

(6) *The amount of direction or guidance presented and (7) the presence or absence of working examples:*

The specification has provided guidance for preparation of a pharmaceutically acceptable salt of a compound embraced by formula (Ia).

Art Unit: 1624

However, the specification does not provide guidance for preparation of a solvate or hydrate of a compound embraced by formula (Ia).

(8) *The quantity of experimentation necessary:*

Considering the state of the art as discussed by the references above, particularly with regards to claims 1-5, 12-14, 16-66, 73, 74, 78-85, 87-92, and 100-109 and the high unpredictability in the art as evidenced therein, and the lack of guidance provided in the specification, one of ordinary skill in the art would be burdened with undue experimentation to practice the invention commensurate in the scope of the claims.

6. Claims 79-81, 83-85, 87-89, and 91 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for treatment of type II diabetes or obesity, does not reasonably provide enablement for the treatment of the scope of disorders claimed. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

The factors to be considered in determining whether a disclosure meets the enablement requirements of 35 U.S.C. 112, first paragraph, have been described in *In re Wands*, 858 F.2d 731, 8 USPQ2d 1400 (Fed. Cir., 1988). The court in *Wands* states, "Enablement is not precluded by the necessity for some experimentation, such as routine screening. However, experimentation needed to practice the invention must not be undue experimentation. The key word is 'undue', not 'experimentation'" (*Wands*, 8 USPQ2d 1404). Clearly, enablement of a claimed invention cannot be predicated on the basis of quantity of experimentation required to make or use the invention. "Whether undue experimentation is needed is not a single, simple factual determination, but rather is a conclusion reached by weighing many factual considerations" (*Wands*, 8 USPQ2d 1404). Among these factors are: (1) the nature of the invention; (2) the breadth of the claims; (3) the state of the prior art; (4) the predictability or unpredictability of the art; (5) the relative skill of those in the art; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary.

Consideration of the relevant factors sufficient to establish a *prima facie* case for lack of enablement is set forth herein below:

(1) *The nature of the invention and (2) the breadth of the claims:*

The claims are drawn to different methods of using a compound in which a pyrimidine ring is modified with a $\text{NH-C(=NR}^8\text{)NHR}^7$ at its 5-position and nitrogen-containing heterocyclic ring at its 4-position. Thus, the claims taken together with the specification imply that a

Art Unit: 1624

compound of the instant application can treat one or more of the disorder recited in claims 79-81, 83-85, 87-89, and 91.

(3) The state of the prior art and (4) the predictability or unpredictability of the art:

Fyfe et al. (*Expert Opinion on Drug Discovery*, **2008**, 3(4), 403-413) describe that GPR119 (also known as RUP3, page 404, first column) agonists treat type II diabetes and obesity because these compounds improve glucose homeostasis while limiting food intake and body weight gain. Fyfe does not describe that RUP3 modulates any other disorders beside type II diabetes and obesity (section 6, pages 410-411).

Diabetes insipidus cannot be prevented ("Type I Diabetes Prevention", <http://diabetes.webmd.com/tc/type-1-diabetes-prevention>, accessed 26 May 2009).

(5) The relative skill of those in the art:

Those of relative skill in the art are those with level of skill of the authors of the references cited to support the examiner's position (MD's, PhD's, or those with advanced degrees and the requisite experience in treatment or prophylaxis of a disease modulated by RUP3).

(6) The amount of direction or guidance presented and (7) the presence or absence of working examples:

The specification has provided guidance for treatment of type II diabetes and obesity.

However, the specification does not provide guidance for the scope of disorders claimed.

(8) The quantity of experimentation necessary:

Considering the state of the art as discussed by the references above, particularly with regards to claims 79-81, 83-85, 87-89, and 91 and the high unpredictability in the art as evidenced therein, and the lack of guidance provided in the specification, one of ordinary skill in the art would be burdened with undue experimentation to practice the invention commensurate in the scope of the claims.

7. The following is a quotation of the second paragraph of 35 U.S.C. 112:

Art Unit: 1624

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

8. Claims 80 and 88 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. These claims contain a "group within a group". The concept of "metabolic syndrome" includes type I diabetes, type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesteremia, dyslipidemia, and syndrome X ("Glucose Metabolism Disorders",

http://www.nlm.nih.gov/cgi/mesh/2011/MB_cgi?mode=&term=Glucose+Metabolism+Disorders&field=entry,accessed 11 January 2011).

Double Patenting

9. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Art Unit: 1624

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

10. Claims 1-5, 12-14, 16-66, 73, 74, 78-85, 87-92, and 100 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-5, 12-14, 16-66, 73, 74, 78-85, 87-92, and 100 of copending Application No. 12/945712 (continuation of 10/541657, filing date of 10 November 2010, priority to 14 January 2003). Although the conflicting claims are not identical, they are not patentably distinct from each other because the first recited compounds of claims 73 and 74 of application 10/541657 are encompassed by the specified claims in both applications. In claims 73 of both applications, the first recited compound is the same. The second compound of claim 74 of application 10/541657 is the same compound as the fourth compound of claim 74 of application 12/945712.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion

11. No claims appear free of the prior art of record.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NOBLE JARRELL whose telephone number is (571)272-9077. The examiner can normally be reached on M-F 8:30 A.M - 5:00 P.M. EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson can be reached on (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1624

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Noble Jarrell/
Primary Examiner, Art Unit 1624